BAYER (BAYRY) Stock Price, News & Analysis

BAYER AG S/ADR (BAYRY) represents interests in Bayer AG, a global enterprise with core competencies in the life science fields of health care and nutrition. According to the company, its products and services are designed to help people and the planet thrive by supporting efforts to address the major challenges of a growing and aging global population. Bayer emphasizes a mission of “Health for all, Hunger for none,” and states that the Bayer brand stands for trust, reliability and quality throughout the world.

Bayer operates across multiple life science areas that align with the Pharmaceutical Preparation Manufacturing industry classification and the broader manufacturing sector. In health care, the company highlights a Pharmaceuticals Division focused on prescription medicines in areas such as oncology, cardiology, neurology, immunology and women’s health. In addition, Bayer reports activities in radiology, including contrast agents and devices for diagnostic imaging, and in cell and gene therapy programs targeting conditions like Parkinson’s disease and ophthalmic diseases. These activities illustrate how the group applies life science research to develop therapies and diagnostic tools.

Beyond pharmaceuticals, Bayer also describes significant activity in crop science and agriculture, which supports the nutrition side of its life science focus. Press materials from Bayer Crop Science Canada reference products such as Sivanto Energy, a foliar insecticide for flea beetle control in canola, and EverGol Rise, a seed treatment aimed at pulse disease control. These examples show how Bayer develops agricultural products intended to help farmers manage pests and diseases in key crops.

The company reports that in fiscal 2024 it employed around 93,000 people and generated sales of 46.6 billion euros, with research and development expenses of 6.2 billion euros or similar figures before special items in some disclosures. While these numbers can change over time, they indicate the scale of Bayer’s global operations and its ongoing investment in R&D across its health care, radiology and agricultural businesses.

Pharmaceuticals and specialty therapeutics

Bayer’s recent communications describe an “ambitious growth strategy” for its Pharmaceuticals Division, with a focus on high-value commercial products and a modality-rich pipeline. The company highlights multiple therapeutic areas:

• Cardiology and cardiovascular-kidney-metabolic (CKM) conditions: Bayer reports advancing treatments and investigational therapies for cardiovascular and renal diseases, including heart failure and chronic kidney disease. It notes regulatory approvals for finerenone (marketed as Kerendia) in certain heart failure settings and describes ongoing Phase III programs such as FINEARTS-HF, MOONRAKER and THUNDERBALL.
• Stroke prevention and thrombosis: Bayer references asundexian, an investigational oral Factor XIa inhibitor studied for secondary stroke prevention. The company notes that a Phase III study (OCEANIC-STROKE) met its primary safety and efficacy endpoints and that asundexian has received Fast Track Designation from the U.S. Food and Drug Administration as a potential treatment for stroke prevention after non-cardioembolic ischemic stroke.
• Oncology: Bayer describes a portfolio that includes Nubeqa (darolutamide) for prostate cancer, with approvals in metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer in certain regions. The company also cites Hyrnuo (sevabertinib) for HER2-mutant non-small cell lung cancer under an accelerated approval in the U.S., and Xofigo (radium-223 dichloride) for metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease. Bayer also reports early-stage oncology programs, including targeted radionuclide therapies and agents aimed at KRAS-mutant cancers and MTAP-deleted tumors.
• Women’s health: Bayer reports regulatory approvals for Lynkuet (elinzanetant) in the EU for moderate to severe vasomotor symptoms due to menopause, including symptoms associated with adjuvant endocrine therapy for breast cancer. In the U.S., Lynkuet is described as an FDA-approved, hormone-free prescription treatment for moderate to severe hot flashes due to menopause. Bayer also continues to develop Mirena (a levonorgestrel-releasing intrauterine system) in new indications, including a Phase III study (SUNFLOWER) investigating treatment of nonatypical endometrial hyperplasia.
• Renal and rare diseases: Bayer highlights BAY 3401016, an investigational monoclonal antibody targeting Semaphorin 3A (Sema3A), being studied in Alport Syndrome, a rare genetic disorder leading to progressive kidney damage. The Phase IIa ASSESS trial is designed to evaluate efficacy and safety in adults with Alport Syndrome, and the program has received Fast Track and Orphan Drug Designations from the FDA.

Radiology and molecular imaging

Bayer describes itself as a global leader in radiology, with a portfolio that includes contrast agents and devices for computed tomography (CT), X-ray, magnetic resonance imaging (MRI) and positron emission tomography (PET), as well as informatics solutions. The company reports that its radiology products generated 2.1 billion euros in sales in 2024.

Recent updates include the investigational MRI contrast agent gadoquatrane, a low-dose gadolinium-based contrast agent with a tetrameric structure and high relaxivity. Bayer’s pivotal QUANTI program, including QUANTI Pediatric, evaluated gadoquatrane in adults and children and showed that it met primary and secondary efficacy endpoints while reducing gadolinium dose compared to certain macrocyclic agents. Bayer has submitted marketing authorization applications for gadoquatrane in markets such as the U.S., EU, Japan and China.

The company also reports expanding into molecular imaging through the acquisition of investigational radiotracers AT-01 and AT-05 from Attralus, designed for the diagnosis of cardiac amyloidosis and other systemic amyloidoses. AT-01, a PET tracer, has FDA Breakthrough Therapy Designation and Orphan Drug Designation in the U.S. and EU. This acquisition is described as supporting Bayer’s broader precision cardiology strategy.

Cell and gene therapy and advanced modalities

Bayer highlights a growing cell and gene therapy portfolio. Examples include:

• Bemdaneprocel, an investigational cell therapy developed with BlueRock Therapeutics, designed to replace dopamine-producing neurons lost in Parkinson’s disease and now in Phase III evaluation.
• AB-1005, an investigational gene therapy from AskBio for moderate-stage Parkinson’s disease, in Phase II study.
• OpCT-001, an iPSC-derived photoreceptor cell therapy for primary photoreceptor diseases, which has received FDA Fast Track designation and is in a Phase I/IIa study.

In cardiology, Bayer mentions AB-1002, an investigational single-dose gene therapy in development for congestive heart failure, and partnerships and designations that support its precision cardiology efforts. The company also reports a collaboration with Soufflé Therapeutics to develop a heart-targeted small interfering RNA (siRNA) therapy for a form of dilated cardiomyopathy, reflecting interest in genetic and RNA-based modalities.

Agriculture and crop science

On the agriculture side, Bayer Crop Science Canada communications describe products such as Sivanto Energy, a foliar insecticide combining deltamethrin and flupyradifurone for flea beetle control in canola, and EverGol Rise, a seed treatment with four active ingredients aimed at controlling seed- and soil-borne diseases in pulse crops, including ascochyta. These offerings illustrate Bayer’s role in supporting crop protection and farm productivity, complementing its health care portfolio and aligning with its nutrition-focused mission.

Mission, sustainability and scale

Across multiple releases, Bayer reiterates its mission “Health for all, Hunger for none” and its commitment to driving sustainable development and generating a positive impact with its businesses. The company states that it aims to increase earning power and create value through innovation and growth, while helping people and the planet thrive. Its recurring disclosure of global employment of around 93,000 people, sales of 46.6 billion euros and multibillion-euro R&D spending in fiscal 2024 underscores the scale of its operations and its focus on research-driven development in pharmaceuticals, radiology and crop science.